Kidney international
-
Kidney international · Apr 2002
Comment Letter Comparative StudyContinuous renal replacement therapy versus intermittent hemodialysis in acute renal failure.
-
Kidney international · Apr 2002
Randomized Controlled Trial Clinical TrialA placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Individuals with chronic renal disease are at high risk of cardiovascular morbidity and mortality, and therefore the management of dyslipidemia is particularly important in this patient population. This double-blind randomized study investigated the efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, atorvastatin, in continuous ambulatory peritoneal dialysis (CAPD) patients with dyslipidemia. ⋯ Atorvastatin was effective in achieving target LDL-cholesterol levels in a high proportion of the dyslipidemic CAPD patients studied at doses that are well tolerated.